Catalent and Perrigo will be able to sell generic versions of Teva's ($TEVA) ProAir HFA inhaler starting in late 2016, resolving a patent dispute between the two parties. Teva had initially sued to block Catalent and Perrigo, saying the pair infringed four of its patents in their plans for a knock-off inhaler. Under the settlement, the two can sell a limited amount of inhalers from Dec. 19, 2016 until June 2018, at which point the restrictions expire.